Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
The role of T cell apoptosis in nervous system autoimmunity.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Determination and characterization of a cannabinoid receptor in rat brain.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Optimizing IFN Beta - 1B Dose (Optims)
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Daclizumab for relapsing remitting multiple sclerosis.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Signal Transduction in the Blood-Brain Barriers
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.

Pages